Cadila

Gilead to challenge hepatitis C drug patent rejection

An order by deputy controller of patents and designs Hardev Karar has said Gilead, which sells the drug under the Sovaldi brand in the US, failed to prove that there were enhancement of therapeutic efficacy in the new discovery.

Healthcare for all: Pharma firms ready to ally with govt, seek aid for innovation

Healthcare in the country at present seems to be 'nobody's baby', says another official of OPPI

Cadila gets approval to market new diabetes drug Lipaglyn in India

Broker Alert: Dump Voltas, Exide has the right mix

Voltas' cooling division is facing increased pressure on the margin front as other players are offering freebies and discounts to liquidate existing inventories.

Markets cheer oil's fall, HPCL & IOC gain

More than the equity market, it's the oil market that is attracting attention. Crude oil, which saw it second-largest fall yesterday, fell further by $5 a barrel.

Earnings Preview: Wipro sales growth may remain muted

Experts expect the company to continue to trail peers and pick up only after the March 2012 quarter. This week, HDFC Bank, Dr Reddy's and Cadila Healthcare are other companies to watch out for.

USFDA raises concerns over drug manufacturing process at Cadila's Guj plant

The U.S. agency communicated its concern to Cadila in a Form 483, a letter in which the agency typically outlines violations of standard manufacturing practices.